Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Palmitoylethanolamide (micronized PEA)

Palmitoylethanolamide (PEA / Micronized PEA) · also known as PEA, Palmitoylethanolamide, Micronized PEA

Palmitoylethanolamide (PEA) is an endogenous human lipid that can activate the PPAR-α receptor. In animal models, it can reduce inflammation and regulate mast cell infiltration, but mast cell and NF-κB-related mechanisms have not been confirmed in humans.

Typical dose: Micronized PEA: 300–1200 mg/day, taken with the morning and evening meals.
Absorption and forms: PEA is highly lipophilic. Coarse crystalline particles dissolve and are absorbed poorly, and micronization may improve this. However, not every effective formulation has to be micronized, and there is no evidence that it must be taken with a fat-containing meal.

Clinical uses and human evidence

Osteoarthritis pain

BeneficialGrade C · Preliminary evidence
Studies (1)
  1. Steels 2019 · Inflammopharmacology · RCT · n=111 — A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis

Peripheral neuropathy (numbness and tingling)

Mixed resultsGrade C · Preliminary evidence
Studies (2)
  1. Cocito 2014 · Pain Res Treat · Open-label study · n=30 — Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain
  2. Pickering 2022 · Inflammopharmacology · RCT · n=70 — A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain

Sleep quality

Mixed resultsGrade C · Preliminary evidence
Studies (2)
  1. Rao 2021 · Sleep Sci Pract · RCT · n=125 — Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study
  2. Pickering 2022 · Inflammopharmacology · RCT · n=70 — A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain

Mechanisms of action

Mast cell membrane stabilization and degranulation blockade

★★★☆☆Mechanism evidence: grade CSecondary target

Mast cell effects come mainly from animal and cell studies. In rat studies, oral PEA can reduce inflammation and lower mast cell infiltration in inflamed tissue. Human pain trials cannot prove this mechanism, and how strongly routine oral doses act on target tissue in humans is unclear.

References (2)
  1. Mazzari et al. 1996 · Rat inflammation model: oral PEA reduced inflammation and suggested modulation of mast cell activation
  2. Petrosino et al. 2018 · Rat study: oral ultramicronized PEA reduced mast cell infiltration in inflamed tissue

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★★☆☆Mechanism evidence: grade CSecondary target

PEA can activate PPAR-α. In mice lacking PPAR-α, some of its anti-inflammatory effects were lost. In inflamed rat tissue, NF-κB signaling also decreased somewhat. Whether routine oral doses can reach enough receptor occupancy in target tissue to produce measurable NF-κB inhibition has not been confirmed in humans.

References (2)
  1. Lo Verme et al. 2005 · Mouse study: some of PEA’s anti-inflammatory effects disappeared in PPAR-α-deficient mice
  2. Petrosino et al. 2018 · Rat oral study: NF-κB p65 nuclear translocation and COX-2 expression fell in inflamed tissue

Safety and drug interactions

PEA is an endogenous human lipid and is generally well tolerated, but that does not make it absolutely safe. Data on long-term use, special populations and use with other drugs are still limited, so people should talk with a doctor first.
Open in the interactive app ›